Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

Abstract: The invention concerns a method for relieving idiopathic ocular pain by administering an effective amount of a fluid composition comprising hyaluronic acid, a hyaluronic acid analogue, or a combination thereof, to the eye of a human or non-human animal subject, wherein the fluid composition is administered after onset of the idiopathic ocular pain and in the absence of detectable signs known to cause ocular pain.

Abstract: Provided herein are purified hemicellulose compositions, sweetener compositions including purified hemicellulose compositions, as well as methods for making the same. Also provided are uses of the compositions.

Abstract: The present invention relates to a process for preparing the telomerase inhibitor imetelstat using a 3 steps per cycle solid-phase support bound process comprising the steps of deprotection of the 3?-amino group of the support-bound oligonucleotide, coupling with a 5?-phosphoramidite, and sulfurization with an acyl disulfide, characterized by the absence of an additional capping step in each cycle that is used to prevent unreacted 3?-amino oligonucleotide groups from reacting during subsequent cycles. Imetelstat has formula below.

Abstract: This disclosure provides a method of administrating to a subject a two-portion solution system in a specific ingesting order to yield a water-insoluble cross-linked hydrogel mass in the stomach. The volume of the formed water-insoluble cross-linked hydrogel mass is at least 50% v/v of the total volume of the two-portion solution system. The method is useful for preventing and treating overweight and obesity.

Abstract: The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.

Abstract: The use of a pharmaceutical composition in treating cancer in a subject comprising a therapeutically effective amount of a compound of formula (I), a therapeutically effective amount of paclitaxel and a low dose of gemcitabine, and a kit included above composition thereof.

Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a myricetin and hesperitin to treat viral infections include coronavirus.

Abstract: Provided herein are methods and compositions for preventing or treating aging, or an aging-related disorder, a disorder associated with inflammation, or for modulating an immune response in a subject in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of a compound of Formulas I-XIII.

Abstract: The invention provides a new method of synthesizing cross-linked hyaluronic acids, compositions thereof, tubes and syringes containing such compositions alone or in combination with PRP/BMC, new devices for PRP/BMC preparation, and uses thereof in cell culture, skincare and joint preservation. The invention provides a method for the production of a crosslinked gel (preferably of desired molecular weight and/or concentration) from at least one first polymer (preferably hyaluronic acid), comprising the steps of: homogenizing said first polymer, hydrating said first polymer in a basic solution, crosslinking said basic solution by adding at the least one crosslinking agent at a higher temperature than room temperature, neutralizing said basic solution in an acidic solution, homogenizing said solution, mixing said solution with a supplemental quantity of a second polymer (preferably a second polymer of substantially the same molecular weight and/or concentration as said first polymer), and purifying said solution.

Abstract: This invention generally relates to the field of compounds and methods for enhanced cellular uptake. In particular, the invention relates to N-acetylgalactosamine compounds and their conjugates. Also provided are methods for the preparation of these molecules and possible uses thereof, in particular in medicine.

Abstract: The present disclosure relates to an improvement in the process of hydrolysis of cellulose to produce nanocellulose using imidazolium-based ionic liquids with short alkyl chains in the presence of transition metal complex and an oxidizing agent.

Abstract: This invention provides, among other things, compounds useful for treating spirochete diseases such as Lyme disease, as well as pharmaceutical formulations and/or environmental baits containing such compounds.

Abstract: A preparation method of a Lentinula edodes polysaccharide rich in ?-glucan includes: (1) extracting the Lentinula edodes polysaccharide to obtain a filtrate; (2) concentrating the filtrate to obtain a supernatant; (3) precipitating a crude Lentinula edodes polysaccharide from the supernatant using anhydrous ethanol to obtain a first precipitate; and (4) purifying the first precipitate to obtain the Lentinula edodes polysaccharide. The Lentinula edodes polysaccharide rich in the ?-glucan has stable quality, and its yield, polysaccharide content and ?-glucan content are significantly improved compared with water extraction and alcohol precipitation methods in the related art. In vitro pharmacological experiments prove that the Lentinula edodes polysaccharide rich in the ?-glucan has good anti-inflammatory activity and can be applied to preparation of drugs or health foods.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: A glycoside compound of fatty acids that includes the general formula: GalNAc-GalNAc-Glc-O—R, where GalNAc is ?- or ?-D-N-acetylgalactosamine, Glc-O—R is a molecule of ?- or ?-D-glucose esterified to a monounsaturated fatty acid (R), where R is selected from 12:1(n) and where n is an integer between 2 and 11; 11:1(n) and where n is an integer between 2 and 10; 10:1(n), and where n is an integer between 2 and 9; 9:1(n), and where n is an integer between 2 and 8; 8:1(n), and where n is an integer between 2 and 8; 7:1(n) and where n is an integer between 2 and 7; and 6:1(n), and where n is an integer between 2 and 6. The compound has activity against plant pathogens, and induces the defense, and promotes the growth, of plants.

Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

Abstract: The present disclosure provides reagent compounds, reactive biopolymeric compounds, and methods of making and using these materials for the rapid and efficient synthesis and purification of biopolymeric compounds at low cost. The materials and methods yield highly pure synthetic biopolymeric compounds, including synthetic oligonucleotides and polypeptides, and reduce or eliminate the need for toxic solvents in the synthetic process.

Abstract: The invention discloses a functionalised chitosan, or a salt thereof, used in the treatment of pathologies of the respiratory tract or hepatic pathologies, preferably caused by viral infections. It was indeed observed that said functionalised chitosan or salt thereof was able to act as galectin-modulator, modulating in particular galectin-3, and therefore determining a marked reduction in the inflammatory and fibrotic cascade generated by these viral infections. The invention moreover discloses a pharmaceutical composition, as well as a biomaterial, comprising this functionalised chitosan, or a salt thereof.

Abstract: Disclosed are compounds, in particular based on polysaccharides, that are adsorbed on a cellulosic material, and relates in particular to the application of such compounds as reinforcing agent for cellulosic materials, in the wet and/or dry state. The compounds include a combination of at least one polysaccharide adsorbed on a cellulosic material, the polysaccharide including at least two different monosaccharide units, forming first and second monosaccharide units, the second monosaccharide units being branched on a chain including at least the first monosaccharide units, at least some of the second monosaccharide units being non-cyclic and bearing aldehyde functions, the aldehyde functions possibly forming hemiacetal functions with hydroxy functions of the cellulosic material.